Imatinib mesylate impairs Flt3L-mediated dendritic cell expansion and antitumor effects in vivo.
D018952:Antigens, CD34 / Q000096:biosynthesis; D000970:Antineoplastic Agents / Q000494:pharmacology; D001549:Benzamides; D002454:Cell Differentiation; D045744:Cell Line, Tumor; D003713:Dendritic Cells / Q000166:cytology* / Q000187:drug effects* / Q000378:metabolism; D016178:Granulocyte-Macrophage Colony-Stimulating Factor / Q000378:metabolism; D006801:Humans; D000068877:Imatinib Mesylate; D007167:Immunotherapy / Q000379:methods; D015847:Interleukin-4 / Q000378:metabolism; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy*; D008565:Membrane Proteins / Q000378:metabolism*; D010879:Piperazines / Q000494:pharmacology*; D011743:Pyrimidines / Q000494:pharmacology*; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D018952:Antigens, CD34; D000970:Antineoplastic Agents; D001549:Benzamides; D008565:Membrane Proteins; D010879:Piperazines; D011743:Pyrimidines; D014409:Tumor Necrosis Factor-alpha; C084881:flt3 ligand protein; D015847:Interleukin-4; D016178:Granulocyte-Macrophage Colony-Stimulating Factor; D000068877:Imatinib Mesylate